FindTrial
Sign In

Realtion of Catalytic iron and Hepcidin with Poor Outcomes in COVID-19 patients

Catalytic iron and hepcidin in patients with COVID-19 and their association with adverse outcomes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/08/027419
Enrollment
49
Registered
2020-08-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Muljibhai Patel Society for Research in NephroUrology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Non-seriously ill COVID-19 patients(WHO1 to 4) 2.Seriously ill COVID-19 positive patients (WHO 5 to 7) 3.Patients with respiratory tract illness, who were initially suspected to have COVID-19, but test negative by RT-PCR test for COVID-19.

Exclusion criteria

Exclusion criteria: Patients with previously known chronic kidney disease, stage 3 above.

Design outcomes

Primary

MeasureTime frame
Composite of acute kidney injury (AKI) requiring dialysis, need for mechanical ventilation and deathTimepoint: 1 month—

Secondary

MeasureTime frame
Death AKI developing after admission Need for mechanical ventilation after admission Worsening of WHO class during hospital stay Length of ICU stay Duration of mechanical ventilation and Serious acute cardiac eventTimepoint: 30 days from admission—

Countries

India

Contacts

Public ContactDr Vipul Chakurkar

KEM Hospital, Pune

chakurkarvipul@gmail.com9403207328

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026